Literature DB >> 30274981

The Role of Angiogenesis in Hepatocellular Carcinoma.

Michael A Morse1, Weijing Sun2, Richard Kim3, Aiwu Ruth He4, Paolo B Abada5, Michelle Mynderse6, Richard S Finn7.   

Abstract

Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is the second leading cause of cancer-related deaths worldwide. The hypervascular nature of most HCC tumors underlines the importance of angiogenesis in the pathobiology of these tumors. Several angiogenic pathways have been identified as being dysregulated in HCC, suggesting they may be involved in the development and pathogenesis of HCC. These data provide practical targets for systemic treatments such as those targeting the vascular endothelial growth factor receptor and its ligand. However, the clinical relevance of other more recently identified angiogenic pathways in HCC pathogenesis or treatment remains unclear. Research into molecular profiles and validation of prognostic or predictive biomarkers will be required to identify the patient subsets most likely to experience meaningful benefit from this important class of agents. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30274981     DOI: 10.1158/1078-0432.CCR-18-1254

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  90 in total

Review 1.  Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.

Authors:  S Perera; D Kelly; G M O'Kane
Journal:  Curr Oncol       Date:  2020-11-01       Impact factor: 3.677

Review 2.  New insights into BMP9 signaling in liver diseases.

Authors:  Qian-Qian Jiang; Bei-Bei Liu; Ke-Shu Xu
Journal:  Mol Cell Biochem       Date:  2021-05-21       Impact factor: 3.396

Review 3.  Challenges in liver cancer and possible treatment approaches.

Authors:  David Anwanwan; Santosh Kumar Singh; Shriti Singh; Varma Saikam; Rajesh Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-11-01       Impact factor: 10.680

4.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

5.  Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity.

Authors:  Manuela Cabiati; Melania Gaggini; Paolo De Simone; Silvia Del Ry
Journal:  Clin Exp Med       Date:  2020-11-17       Impact factor: 3.984

6.  HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.

Authors:  Peizhan Chen; Xiaohua Duan; Xiaoguang Li; Jingquan Li; Qian Ba; Hui Wang
Journal:  Oncogene       Date:  2020-02-07       Impact factor: 9.867

Review 7.  MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.

Authors:  Chi Ma; Qianfei Zhang; Tim F Greten
Journal:  Cell Immunol       Date:  2021-01-21       Impact factor: 4.868

Review 8.  Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.

Authors:  A Weinmann; P R Galle
Journal:  Curr Oncol       Date:  2020-11-01       Impact factor: 3.677

Review 9.  Immunotherapy Updates in Advanced Hepatocellular Carcinoma.

Authors:  Amisha Singh; Ryan J Beechinor; Jasmine C Huynh; Daneng Li; Farshid Dayyani; Jennifer B Valerin; Andrew Hendifar; Jun Gong; May Cho
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

10.  Sec62 promotes pro-angiogenesis of hepatocellular carcinoma cells under hypoxia.

Authors:  Yongbin Meng; Hetong Zhao; Zhihao Zhao; Zifei Yin; Zhe Chen; Juan Du
Journal:  Cell Biochem Biophys       Date:  2021-06-12       Impact factor: 2.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.